BeiGene to Present New Data from SEQUOIA Study Evaluating BRUKINSA® plus Venetoclax in High-Risk First-Line CLL/SLL at EHA2024
BeiGene and NewBridge Pharmaceuticals FZ LLC Mutually Agree to Conclude BRUKINSA® (Zanubrutinib) Partnership in the Middle East and Africa (MENA) Region
Glenmark Pharmaceuticals on Tuesday said its unit has inked a marketing and distribution agreement with BeiGene to commercialise the latter's oncology medicines, Tislelizumab and Zanubrutinib in India.
First Doses of BRUKINSA® provided to Patients with Chronic Lymphocytic Leukemia
March 7 (Reuters) - The U.S. Food and Drug Administration has granted accelerated approval for the expanded use of BeiGene's (6160.HK), opens new tab combination drug to treat certain patients with a type of blood cancer, the health regulator said on Thursday.
BeiGene Announces FDA Accelerated Approval of BRUKINSA
FDA Confirms Paragraph IV Patent Litigation for Zanubrutinib Capsules
BeiGene`s Brukinsa (zanubrutinib) Receives Approval in Europe
China's BeiGene, a global, science-driven biotechnology company, has announced that its anti-cancer drug zanubrutinib, a Bruton’s tyrosine kinase inhibitor (BTKi), has been added to Singapore’s Ministry of Health (MoH) Cancer Drug List (CDL) for multiple indications.
BeiGene Receives European Commission Approval for BRUKINSA